400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2024-10-30
生物制药商
医药研发/制造
化学&生物药
Soleus Capital;
Soleus Capital;
Sands Capital;
Sands Capital;
Bracco Imaging;
Woodline Partners;
PBM Capital Group
2023-08-14
基因治疗药物研发商
医药研发/制造
化学&生物药
八方资本;
八方资本;
Venrock Capital;
Venrock Capital;
Invus;
PBM Capital Group;
RTW Investments;
RA Capital;
Acuta;
GordonMD Global Investments;
2021-09-09
临床阶段基因治疗疗法研发商
医药研发/制造
化学&生物药
Eventide Asset Management;
Eventide Asset Management;
D1 Capital Partners;
D1 Capital Partners;
Alexandria Venture Investments;
Invus;
Woodline Partners;
Janus Henderson Investors;
PBM Capital Group;
Lundbeckfonden Ventures;
Omega Funds;
Longitude Capital;
Gray's Creek Capital Partners;
Laurion Capital Management;
Verition Fund Management;
CAM Capital
2021-05-28
基因组诊断系统研发商
其他
2021-02-09
个性化健康网络平台服务商
学术研究
综合服务
Symphony Ventures;
Symphony Ventures;
Hambrecht Ducera;
Hambrecht Ducera;
Optum Ventures;
Alta Partners;
PBM Capital Group
2021-01-07
临床阶段基因治疗疗法研发商
医药研发/制造
化学&生物药
Omega Funds;
Omega Funds;
Longitude Capital;
Longitude Capital;
Alexandria Venture Investments;
Alzheimer's Drug Discovery Foundation;
Woodline Partners;
Invus;
Janus Henderson Investors;
PBM Capital Group;
Lundbeckfonden Ventures
2020-08-05
基因治疗药物研发商
医药研发/制造
化学&生物药
GV;
GV;
Invus;
Invus;
Franklin Templeton Investments;
Nolan Capital;
Casdin Capital;
Perceptive Advisors;
BlackRock;
Venrock Capital;
富达国际;
PBM Capital Group;
ArrowMark Partners;
八方资本;
Sands Capital Ventures
2020-07-17
生物新药研发商
医药研发/制造
化学&生物药
Samsara BioCapital;
Samsara BioCapital;
Perceptive Advisors;
Perceptive Advisors;
RA Capital;
Access Industries;
Aisling Capital;
奥博资本;
Sphera Global Healthcare Fund;
Abingworth;
诺和诺德;
New Enterprise Associate;
Foresite Capital;
Soleus Capital;
PBM Capital Group;
Acorn Bioventures
2020-04-30
失明症治疗用基因药物研发商
医药研发/制造
化学&生物药
Foundation Fighting Blindness;
Foundation Fighting Blindness;
Hatteras Venture Partners;
Hatteras Venture Partners;
University of Florida;
PBM Capital Group;
Osage University Partners
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10